BIOMAT Database Logo BIOMAT Database Logo

Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals. 2017

Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Department of Infectious Diseases, Hospital Universitario Ramon y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain sergio.serrano@salud.madrid.org.

A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts death. The effects of different antiretroviral therapy regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind trial of maraviroc versus efavirenz in combination with zidovudine-lamivudine in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by a greater CD8+ T-cell decline.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003510 Cyclohexanes Six-carbon alicyclic hydrocarbons.
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077592 Maraviroc A cyclohexane and triazole derivative that acts as an antagonist of the CCR5 RECEPTOR. It prevents infection by HIV-1 virus strains which use CCR5 as a co-receptor for membrane fusion and cellular entry. 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide,Selzentry,UK-427,857,UK-427857,UK 427,857,UK 427857,UK427,857,UK427857

Related Publications

Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
March 2010, The Journal of infectious diseases,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
October 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
February 2008, Clinical therapeutics,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
[Cost-effectiveness analysis of tenofovir versus zidovudine in combination therapy with efavirenz and lamivudine for the treatment of HIV in naive patients].
January 2005, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients.
January 2017, The Journal of antimicrobial chemotherapy,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
October 2008, The Journal of infectious diseases,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
September 2000, Antiviral therapy,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
January 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
January 2003, HIV clinical trials,
Sergio Serrano-Villar, and Giorgia Caruana, and Alexander Zlotnik, and José A Pérez-Molina, and Santiago Moreno
Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.
March 1998, AIDS (London, England),
Copied contents to your clipboard!